Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Monday

Key Points

• Syndax Pharmaceuticals is scheduled to report Q3 2026 results after the market closes on Monday, November 2. Analysts expect a loss of $0.4848 per share and revenue of approximately $81.91 million.
• The company’s previous quarter fell short of expectations, posting a $0.55-per-share loss versus the estimated $0.45 loss and revenue of $72.79 million versus $79.36 million expected. However, revenue increased 91.8% year over year.
• Wall Street maintains a generally positive view, with a consensus “Moderate Buy” rating and an average price target of $41.80, despite shares opening at $13.40 and trading near their 12-month low.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.4848) per share and revenue of $81.91 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The business had revenue of $72.79 million during the quarter, compared to analyst estimates of $79.36 million. Syndax Pharmaceuticals had a negative net margin of 87.52% and a negative return on equity of 372.94%. The business's revenue for the quarter was up 91.8% on a year-over-year basis. During the same period last year, the company earned ($0.83) EPS. On average, analysts expect Syndax Pharmaceuticals to post ($2.01) EPS for the current fiscal year and ($1.01) EPS for the next fiscal year.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ:SNDX opened at $13.40 on Monday. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -5.34 and a beta of 0.42. Syndax Pharmaceuticals has a 12-month low of $12.80 and a 12-month high of $25.59. The business has a 50-day moving average price of $17.82 and a 200 day moving average price of $19.79. The company has a current ratio of 6.77, a quick ratio of 6.44 and a debt-to-equity ratio of 38.95.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. UBS Group reaffirmed a "buy" rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. JPMorgan Chase & Co. reduced their price target on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 11th. Bank of America restated a "buy" rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. Jefferies Financial Group restated a "buy" rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, September 29th. Finally, Weiss Ratings cut shares of Syndax Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, October 19th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $41.80.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc NASDAQ: SNDX is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax's lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.